CD8A and neoplasm: Tumor cells can trigger the PD‐1 pathway to escape the anti‐tumor immune response, and PD‐1 or PD‐L1 inhibitors can restore T‐cell signaling, with subsequent reactivation of the antitumor activity of specific CD8+T cells.